Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort
Introduction We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa.Methods We included all patients aged 0–24 years on ART from nine clinics in Côte d’Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/10/1/e016512.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527912216395776 |
|---|---|
| author | Valériane Leroy Anandi Sheth Julie Jesson Jean Jacques Koffi Antoine Jaquet François Dabis Didier Koumavi Ekouevi Karen Malateste Olivia Keiser Lehila Bagnan Simon Boni Madeleine Amorissani Folquet Mariam Sylla Olivier Marcy Raoul Moh Gildas Boris Hedible Sophie Desmonde Joycelyn Dame Agatha David Madeleine Amorissani-Folquet Sylvie N'Gbeche Elom Takassi François Tanoh Eboua Kouadio Kouakou Lehila Bagnan Tossa Caroline Yonaba Jocelyn Dame Sylvie Marie N’Gbeche Fatoumata Dicko Traore Oliver Ezchechi Rosemary Audu Charlotte Bernard Caroline Couturier Marie Kerbie Plaisy Elodie Rabourdin Thierry Tiendrebeogo Désiré Dahourou Emile Sodinyessi Jean-Claude Azani Kadidja Diarra Maika Bengali Abdoulaye Cissé Guy Gnepa Eric Komena Séverin Lenaud Eulalie Kangah Igho Ofotokun Cecile Delille Lahiri Noëlle Benzekri Geoffrey Gottlieb |
| author_facet | Valériane Leroy Anandi Sheth Julie Jesson Jean Jacques Koffi Antoine Jaquet François Dabis Didier Koumavi Ekouevi Karen Malateste Olivia Keiser Lehila Bagnan Simon Boni Madeleine Amorissani Folquet Mariam Sylla Olivier Marcy Raoul Moh Gildas Boris Hedible Sophie Desmonde Joycelyn Dame Agatha David Madeleine Amorissani-Folquet Sylvie N'Gbeche Elom Takassi François Tanoh Eboua Kouadio Kouakou Lehila Bagnan Tossa Caroline Yonaba Jocelyn Dame Sylvie Marie N’Gbeche Fatoumata Dicko Traore Oliver Ezchechi Rosemary Audu Charlotte Bernard Caroline Couturier Marie Kerbie Plaisy Elodie Rabourdin Thierry Tiendrebeogo Désiré Dahourou Emile Sodinyessi Jean-Claude Azani Kadidja Diarra Maika Bengali Abdoulaye Cissé Guy Gnepa Eric Komena Séverin Lenaud Eulalie Kangah Igho Ofotokun Cecile Delille Lahiri Noëlle Benzekri Geoffrey Gottlieb |
| collection | DOAJ |
| description | Introduction We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa.Methods We included all patients aged 0–24 years on ART from nine clinics in Côte d’Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and Burkina Faso. Baseline varied by clinic and was defined as date of first DTG prescription; patients were followed up until database closure/death/loss to follow-up (LTFU, no visit ≥7 months), whichever came first. We computed the cumulative incidence function for DTG initiation; associated factors were explored in a shared frailty model, accounting for clinic heterogeneity.Results Since 2019, 3350 patients were included; 47.2% were female; 78.9% had been on ART ≥12 months. Median baseline age was 12.5 years (IQR 8.4–15.8). Median follow-up was 14 months (IQR 7–22). The overall cumulative incidence of DTG initiation reached 22.7% (95% CI 21.3 to 24.2) and 56.4% (95% CI 54.4 to 58.4) at 12 and 24 months, respectively. In univariate analyses, those aged <5 years and female were overall less likely to switch. Adjusted on ART line and available viral load (VL) at baseline, females aged >10 years were less likely to initiate DTG compared with males of the same age (adjusted HR among 10–14 years: 0.62, 95% CI 0.54 to 0.72; among ≥15 years: 0.43, 95% CI 0.36 to 0.50), as were those with detectable VL (>50 copies/mL) compared with those in viral suppression (aHR 0.86, 95% CI 0.77 to 0.97) and those on PIs compared with those on non-nucleoside reverse-transcriptase inhibitors (aHR after 12 months of roll-out: 0.75, 95% CI 0.65 to 0.86).Conclusion Paediatric DTG uptake was incomplete and unequitable in west African settings: DTG use was least likely in children <5 years, females ≥10 years and those with detectable VL. Maintained monitoring and support of treatment practices is required to better ensure universal and equal uptake. |
| format | Article |
| id | doaj-art-926b4f2c0ee8477ab7b6d887b90e1a1d |
| institution | Kabale University |
| issn | 2059-7908 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Global Health |
| spelling | doaj-art-926b4f2c0ee8477ab7b6d887b90e1a1d2025-01-15T04:45:09ZengBMJ Publishing GroupBMJ Global Health2059-79082025-01-0110110.1136/bmjgh-2024-016512Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort Valériane Leroy0Anandi ShethJulie JessonJean Jacques KoffiAntoine JaquetFrançois DabisDidier Koumavi EkoueviKaren Malateste1Olivia KeiserLehila BagnanSimon BoniMadeleine Amorissani FolquetMariam Sylla2Olivier MarcyRaoul MohGildas Boris HedibleSophie Desmonde3Joycelyn Dame4Agatha David5Madeleine Amorissani-Folquet6Sylvie N'Gbeche7Elom Takassi8François Tanoh Eboua9Kouadio Kouakou10Lehila Bagnan Tossa11Caroline Yonaba12Jocelyn DameSylvie Marie N’GbecheFatoumata Dicko TraoreOliver EzchechiRosemary AuduCharlotte BernardCaroline CouturierMarie Kerbie PlaisyElodie RabourdinThierry TiendrebeogoDésiré DahourouEmile SodinyessiJean-Claude AzaniKadidja DiarraMaika BengaliAbdoulaye CisséGuy GnepaEric KomenaSéverin LenaudEulalie KangahIgho OfotokunCecile Delille LahiriNoëlle BenzekriGeoffrey Gottlieb1 CERPOP, Toulouse, France3 Research Institute for Sustainable Development (IRD) EMR 271, INSERM U1219, Bordeaux, France7 Gabriel Touré University Hospital Center, Bamako, Mali1 CERPOP, Toulouse, France2 Korle Bu Teaching Hospital, Accra, Ghana4 Clinical Sciences Department, Nigerian Institute of Medical Research, Lagos, Nigeria5 Pediatrics, Cocody University Hospital, Abidjan, Côte d`Ivoire6 CEPREF, Abidjan, Côte d`Ivoire8 Sylvanus Olympio University Hospital Center, Lome, Togo9 University Hospital of Yopougon, Abidjan, Côte d`Ivoire10 CIRBA, Abidjan, Côte d`Ivoire11 Centre National Hospitalier et Universitaire de Cotonou, Cotonou, Benin12 University Hospital Yalgado Ouedraogo, Ouagadougou, Centre, Burkina FasoIntroduction We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa.Methods We included all patients aged 0–24 years on ART from nine clinics in Côte d’Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and Burkina Faso. Baseline varied by clinic and was defined as date of first DTG prescription; patients were followed up until database closure/death/loss to follow-up (LTFU, no visit ≥7 months), whichever came first. We computed the cumulative incidence function for DTG initiation; associated factors were explored in a shared frailty model, accounting for clinic heterogeneity.Results Since 2019, 3350 patients were included; 47.2% were female; 78.9% had been on ART ≥12 months. Median baseline age was 12.5 years (IQR 8.4–15.8). Median follow-up was 14 months (IQR 7–22). The overall cumulative incidence of DTG initiation reached 22.7% (95% CI 21.3 to 24.2) and 56.4% (95% CI 54.4 to 58.4) at 12 and 24 months, respectively. In univariate analyses, those aged <5 years and female were overall less likely to switch. Adjusted on ART line and available viral load (VL) at baseline, females aged >10 years were less likely to initiate DTG compared with males of the same age (adjusted HR among 10–14 years: 0.62, 95% CI 0.54 to 0.72; among ≥15 years: 0.43, 95% CI 0.36 to 0.50), as were those with detectable VL (>50 copies/mL) compared with those in viral suppression (aHR 0.86, 95% CI 0.77 to 0.97) and those on PIs compared with those on non-nucleoside reverse-transcriptase inhibitors (aHR after 12 months of roll-out: 0.75, 95% CI 0.65 to 0.86).Conclusion Paediatric DTG uptake was incomplete and unequitable in west African settings: DTG use was least likely in children <5 years, females ≥10 years and those with detectable VL. Maintained monitoring and support of treatment practices is required to better ensure universal and equal uptake.https://gh.bmj.com/content/10/1/e016512.full |
| spellingShingle | Valériane Leroy Anandi Sheth Julie Jesson Jean Jacques Koffi Antoine Jaquet François Dabis Didier Koumavi Ekouevi Karen Malateste Olivia Keiser Lehila Bagnan Simon Boni Madeleine Amorissani Folquet Mariam Sylla Olivier Marcy Raoul Moh Gildas Boris Hedible Sophie Desmonde Joycelyn Dame Agatha David Madeleine Amorissani-Folquet Sylvie N'Gbeche Elom Takassi François Tanoh Eboua Kouadio Kouakou Lehila Bagnan Tossa Caroline Yonaba Jocelyn Dame Sylvie Marie N’Gbeche Fatoumata Dicko Traore Oliver Ezchechi Rosemary Audu Charlotte Bernard Caroline Couturier Marie Kerbie Plaisy Elodie Rabourdin Thierry Tiendrebeogo Désiré Dahourou Emile Sodinyessi Jean-Claude Azani Kadidja Diarra Maika Bengali Abdoulaye Cissé Guy Gnepa Eric Komena Séverin Lenaud Eulalie Kangah Igho Ofotokun Cecile Delille Lahiri Noëlle Benzekri Geoffrey Gottlieb Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort BMJ Global Health |
| title | Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort |
| title_full | Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort |
| title_fullStr | Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort |
| title_full_unstemmed | Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort |
| title_short | Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort |
| title_sort | disparities in dolutegravir utilisation in children adolescents and young adults 0 24 years living with hiv an analysis of the iedea pediatric west african cohort |
| url | https://gh.bmj.com/content/10/1/e016512.full |
| work_keys_str_mv | AT disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT valerianeleroy disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT anandisheth disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT juliejesson disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT jeanjacqueskoffi disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT antoinejaquet disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT francoisdabis disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT didierkoumaviekouevi disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT karenmalateste disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT oliviakeiser disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT lehilabagnan disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT simonboni disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT madeleineamorissanifolquet disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT mariamsylla disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT oliviermarcy disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT raoulmoh disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT gildasborishedible disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT sophiedesmonde disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT joycelyndame disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT agathadavid disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT madeleineamorissanifolquet disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT sylviengbeche disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT elomtakassi disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT francoistanoheboua disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT kouadiokouakou disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT lehilabagnantossa disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT carolineyonaba disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT jocelyndame disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT sylviemariengbeche disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT fatoumatadickotraore disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT oliverezchechi disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT rosemaryaudu disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT charlottebernard disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT carolinecouturier disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT mariekerbieplaisy disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT elodierabourdin disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT thierrytiendrebeogo disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT desiredahourou disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT emilesodinyessi disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT jeanclaudeazani disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT kadidjadiarra disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT maikabengali disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT abdoulayecisse disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT guygnepa disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT erickomena disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT severinlenaud disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT eulaliekangah disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT ighoofotokun disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT ceciledelillelahiri disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT noellebenzekri disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort AT geoffreygottlieb disparitiesindolutegravirutilisationinchildrenadolescentsandyoungadults024yearslivingwithhivananalysisoftheiedeapediatricwestafricancohort |